A Phase 1 interventional study of Sapanisertib and Paclitaxel in Non-hematologic Malignancy, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-28.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to characterize the effect of a high-fat meal on the pharmacokinetics (PK) of sapanisertib milled API capsules, and to characterize the PK of sapanisertib milled API capsules when administered on an empty stomach approximately 24 hours after paclitaxel infusion.
The drug being tested in this study is called sapanisertib (MLN0128). Sapanisertib is being tested to assess its safety and tolerability when administered alone or in combination with paclitaxel in people who have nonhematologic malignancies. Sapanisertib is also being tested to characterize its PK properties (how is processed by the body) when administered with a high-fat meal compared to on an empty stomach. This study will look at side effects and lab results in people who take sapanisertib with or without paclitaxel.
This open label study enrolled 61 patients. Participants receiving only sapanisertib will participate in a 6-day PK Run-In Period where sapanisertib 4 mg capsules are administered under fasted conditions on Days 1 and 4, and with a high-fat breakfast on Day 3. The main treatment period will begin within 14 days from Day 6 of the PK Run-In Period. In the main treatment period participants will receive sapanisertib 4 mg daily in a 28-day Cycle for up to 12 cycles. Participants in the treatment arm receiving sapanisertib and paclitaxel will not have a PK Run-In Period and will receive sapanisertib 6 mg daily on Days 2-4, 9-11, 16-18, and 23-25 in a 28-day Cycle for up to 12 cycles and paclitaxel 80 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 in 28-day Cycle, for up to 12 cycles. The dose of sapanisertib may be modified based on safety and tolerability during each 28-day cycle in either treatment arm.
This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 15 months. Participants in the sapanisertib only arm will make up to 32 visits to the clinic and participants in the sapanisertib and paclitaxel arm will make up to 26 visits to the clinic. All participants will make a final visit to the clinic 30 days after the last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has adequate organ function, including the following:
Is a female participants who:
Male participants, even if surgically sterilized (ie, status postvasectomy), who:
Exclusion Criteria:
Has significant active cardiovascular disease including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
Drug: Sapanisertib
Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
Drug: Sapanisertib
Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m\^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
Drug: Sapanisertib · Drug: Paclitaxel
Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m\^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
Drug: Sapanisertib · Drug: Paclitaxel
Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
Drug: Sapanisertib
Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
Drug: Sapanisertib
Sapanisertib capsules
Paclitaxel injection
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 15 months)
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions
Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)
Progression Free Survival (PFS)
PFS is defined as the time from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)
Clinical Benefit Response (CBR)
CBR is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD is neither shrinkage by greater than or equal to 30% of the sum of the longest diameter of target lesions or the increase of lesions by greater than or equal to 20% of the sum of the longest diameter of target lesions.
Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)
Change From Baseline in Tumor Volume/Size
Changes in tumor size and volume will be determined by measurements from computed tomography (CT) and magnetic resonance imaging (MRI) scans.
Time frame: From Cycle 1 Day -14 to 14 months
Participants took part in the study at 4 investigative sites in United States from 26 March 2015 to 31 May 2018.
| Milestone | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|
| Started | 11 | 8 | 7 | 15 | 7 | 13 |
| Safety population | 11 | 6 | 7 | 15 | 7 | 13 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 8 | 7 | 15 | 7 | 13 |
| Withdrew: Adverse event | 0 | 2 | 0 | 3 | 0 | 3 |
| Withdrew: Progressive disease | 6 | 4 | 4 | 9 | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Received drug in run-in and discontinued | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 2 | 1 | 2 | 6 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | PK-Run In Period Fasted (Unmilled) | PK-Run In Period Fed (Milled) | PK-Run In Period Fasted (Milled) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|---|---|---|
| At least one AE | 7 | 6 | 9 | 11 | 6 | 7 | 14 | 6 | 13 |
| Serious AE | 1 | 0 | 2 | 3 | 2 | 2 | 7 | 4 | 7 |
| ng/mL | Sapanisertib 4 mg Milled Capsules Under Fed Conditions | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions |
|---|---|---|
| Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions | 21.6 ± 37.4 | 36.4 ± 50.6 |
| ng*hr/mL | Sapanisertib 4 mg Milled Capsules Under Fed Conditions | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions |
|---|---|---|
| Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions | 205.9 ± 59.8 | 229.2 ± 58.2 |
| ng*hr/mL | Sapanisertib 4 mg Milled Capsules Under Fed Conditions | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions |
|---|---|---|
| Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions | 382.8 ± 64.7 | 369.2 ± 50.0 |
| ng/mL | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion | 35.2 ± 22.33 | 71.4 ± 29.16 |
| hours | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion | 2.2 (0.9 to 5.6) | 1.1 (0.5 to 3.0) |
| ng*hr/mL | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|
| AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion | 144.8 ± 84.15 | 260.6 ± 89.59 |
| ng/mL | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions | Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|
| Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions | 36.4 ± 50.6 | 34.0 ± 48.1 | 208.6 ± 17.3 | 235.2 ± 43.4 |
| hr*ng/mL | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions | Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|
| Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions | 229.2 ± 58.2 | 204.6 ± 57.3 | 1238.1 ± 53.3 | 1528.8 ± 43.5 |
| hr*ng/mL | Sapanisertib 4 mg Milled Capsules Under Fasted Conditions | Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|
| AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions | 369.2 ± 50.0 | 400.8 ± 48.2 | 1326.2 ± 61.5 | 1636.6 ± 45.2 |
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
| percentage of participants | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|
| Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) | 9.1 | 16.7 | 14.3 | 20.0 | 0.0 | 0.0 |
PFS is defined as the time from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
CBR is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD is neither shrinkage by greater than or equal to 30% of the sum of the longest diameter of target lesions or the increase of lesions by greater than or equal to 20% of the sum of the longest diameter of target lesions.
| percentage of participants | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|
| CR+PR+SD | 63.6 | 33.3 | 42.9 | 53.3 | 42.9 | 46.2 |
| CR + PR + SD (>= 6 Months) | 36.4 | 33.3 | 14.3 | 26.7 | 0.0 | 7.7 |
Changes in tumor size and volume will be determined by measurements from computed tomography (CT) and magnetic resonance imaging (MRI) scans.
No measurements were reported for this outcome.
Collected over From first dose of study drug up to 30 days post last dose (Up to 15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PK-Run In Period Fasted (Unmilled) | 0/19 (0%) | 1/19 (5.3%) | 7/19 (36.8%) |
| PK-Run In Period Fed (Milled) | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| PK-Run In Period Fasted (Milled) | 0/17 (0%) | 2/17 (11.8%) | 9/17 (52.9%) |
| Single-Agent QD Arm: Sapanisertib 3 mg | 0/11 (0%) | 3/11 (27.3%) | 11/11 (100%) |
| Single-Agent QD Arm: Sapanisertib 4 mg | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | 1/15 (6.7%) | 7/15 (46.7%) | 14/15 (93.3%) |
| Single-Agent QW Arm: Sapanisertib 20 mg | 0/7 (0%) | 4/7 (57.1%) | 6/7 (85.7%) |
| Single-Agent QW Arm: Sapanisertib 30 mg | 1/13 (7.7%) | 7/13 (53.8%) | 12/13 (92.3%) |
| Event | PK-Run In Period Fasted (Unmilled) | PK-Run In Period Fed (Milled) | PK-Run In Period Fasted (Milled) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|---|---|---|
| HypotensionVascular disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 1/15 | 2/7 | 0/13 |
| Blood creatinine increasedInvestigations | 1/19 | 0/19 | 0/17 | 0/11 | 1/6 | 0/7 | 1/15 | 0/7 | 0/13 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 0/19 | 0/17 | 0/11 | 1/6 | 0/7 | 0/15 | 0/7 | 0/13 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 0/7 | 2/13 |
| Cardiac failure congestiveCardiac disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 1/7 | 0/13 |
| Abdominal painGastrointestinal disorders | 0/19 | 0/19 | 0/17 | 1/11 | 0/6 | 1/7 | 1/15 | 1/7 | 1/13 |
| DysphagiaGastrointestinal disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 1/7 | 0/13 |
| Intestinal obstructionGastrointestinal disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 1/7 | 0/13 |
| Enterococcal sepsisInfections and infestations | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 1/7 | 0/13 |
| Tracheal obstructionInjury, poisoning and procedural complications | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 0/7 | 0/15 | 1/7 | 0/13 |
| Event | PK-Run In Period Fasted (Unmilled) | PK-Run In Period Fed (Milled) | PK-Run In Period Fasted (Milled) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/19 | 0/19 | 1/17 | 5/11 | 1/6 | 5/7 | 6/15 | 4/7 | 6/13 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 0/19 | 0/17 | 2/11 | 4/6 | 5/7 | 8/15 | 4/7 | 2/13 |
| FatigueGeneral disorders | 0/19 | 0/19 | 1/17 | 6/11 | 4/6 | 2/7 | 9/15 | 3/7 | 8/13 |
| StomatitisGastrointestinal disorders | 0/19 | 0/19 | 0/17 | 1/11 | 2/6 | 4/7 | 4/15 | 0/7 | 2/13 |
| PruritusSkin and subcutaneous tissue disorders | 0/19 | 0/19 | 0/17 | 6/11 | 3/6 | 0/7 | 0/15 | 0/7 | 1/13 |
| VomitingGastrointestinal disorders | 4/19 | 1/19 | 2/17 | 3/11 | 1/6 | 2/7 | 5/15 | 2/7 | 7/13 |
| Decreased appetiteMetabolism and nutrition disorders | 1/19 | 0/19 | 0/17 | 4/11 | 2/6 | 3/7 | 8/15 | 2/7 | 2/13 |
| Neuropathy peripheralNervous system disorders | 0/19 | 0/19 | 0/17 | 0/11 | 0/6 | 3/7 | 2/15 | 0/7 | 0/13 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/19 | 0/19 | 0/17 | 4/11 | 0/6 | 2/7 | 0/15 | 0/7 | 2/13 |
| Upper respiratory tract infectionInfections and infestations | 0/19 | 0/19 | 0/17 | 0/11 | 2/6 | 1/7 | 0/15 | 0/7 | 1/13 |
All enrolled participants.
| Age, Continuous(years) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 62.5 ± 15.76 | 60.5 ± 8.17 | 56.2 ± 7.75 | 63.4 ± 12.74 | 57.0 ± 16.45 | 60.5 ± 12.02 | 60.7 ± 12.47 |
| Sex: Female, Male(Participants) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 6 | 5 | 11 | 3 | 10 | 44 |
| Male | 2 | 2 | 2 | 4 | 4 | 3 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 11 | 8 | 7 | 14 | 6 | 12 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 2 | 1 | 1 | 7 |
| White | 9 | 7 | 6 | 11 | 5 | 11 | 49 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| United States | 11 | 8 | 7 | 15 | 7 | 13 | 61 |
| Height(cm) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 163.9 ± 7.78 | 168.0 ± 8.52 | 170.2 ± 6.68 | 166.0 ± 11.43 | 165.3 ± 11.92 | 164.4 ± 5.05 | 165.9 ± 8.76 |
| Weight(kg) | Single-Agent QD Arm: Sapanisertib 3 mg | Single-Agent QD Arm: Sapanisertib 4 mg | Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2 | Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2 | Single-Agent QW Arm: Sapanisertib 20 mg | Single-Agent QW Arm: Sapanisertib 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 71.2 ± 17.02 | 74.4 ± 14.11 | 87.2 ± 35.23 | 75.3 ± 27.45 | 63.3 ± 15.55 | 61.8 ± 11.10 | 71.6 ± 21.96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Mar 2015 to primary completion in May 2018, 38 months.
Results were first posted in Feb 2020, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Millennium Pharmaceuticals, Inc. →